Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NEUROSENSE THERAPEUTICS LTD.

(NRSN)
  Report
Delayed Nasdaq  -  03:59 2022-10-07 pm EDT
1.690 USD   -1.17%
09/28NeuroSense Reports Positive Results From Study of Treatment for Amyotrophic Lateral Sclerosis; Shares Rise
MT
09/28NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US
PR
09/28NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NeuroSense Therapeutics : Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC - Form 6-K

06/01/2022 | 09:12am EDT

NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

Phase IIa study successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biomarkers
PrimeC has Orphan Drug Designation with the FDA and EMA

CAMBRIDGE, Mass., June 1st, 2022 -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has enrolled the first patient in its Phase IIb PARADIGM trial for its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM will enroll 69 people living with ALS in Israel, Italy, and the U.S. The double blind, placebo controlled, multicenter trial will randomize participants at a 2:1 ratio to receive PrimeC or placebo, respectively. Clinical trial endpoints include assessment of ALS-biomarkers, evaluation of clinical efficacy, and improvement in quality of life to demonstrate an attenuation in disease progression. NeuroSense expects to complete enrollment by the end of 2022 and to report top-line results in Q2 2023.

NeuroSense enrolls first patient in PARADIGM,
a Phase IIb trial for ALS with their novel
combination therapy, PrimeC

PrimeC is a novel, patented formulation consisting of specific doses of two FDA-approved drugs, ciprofloxacin and celecoxib, designed to work synergistically on multiple targets by regulating microRNA synthesis, modulating iron accumulation, and reducing neuroinflammation. The Phase IIb study is designed to utilize an optimized dose and improved formulation which aims to maximize the synergistic effect between the compounds in the combination drug, relative to the formulation used in the prior Phase IIa study.

"As PrimeC enters this advanced stage trial, we are hopeful that our enhanced formulation will further improve on the promising results we observed from our combination therapy in our Phase IIa ALS study," stated NeuroSense's CEO, Alon Ben-Noon. "In this well-designed, patient-centric study, we are working in collaboration with cutting-edge technology partners on an extensive panel of biomarkers to elucidate PrimeC's mechanism of action, as we believe this could enable patient stratification and increase likelihood of success in a pivotal trail. Targeting multiple pathological pathways in ALS, synergistically, is a paradigm shift in ALS therapy".

About PrimeC

PrimeC, NeuroSense's lead drug candidate is a combination therapy that was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). NeuroSense completed a Phase IIa clinical study which successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC's biological activity. Through a collaboration with Massachusetts General Hospital in Boston on novel Neuron-Derived Exosomes (NDEs), NeuroSense is working to further determine the biological changes in ALS-related pathologies and the effect of PrimeC on relevant targets. Results from this study are expected Q2 2022.

About ALS

Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 patients are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of patients with ALS is expected to grow 24% by 2040 in the U.S. and EU.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding patent applications; the company's PrimeC development program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of enrolment, completion and reporting of results from current and future clinical trials; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.

For further information: Email: info@neurosense-tx.com, Tel: +972 (0)9 799 6183

Disclaimer

Neurosense Therapeutics Ltd. published this content on 01 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 June 2022 13:11:05 UTC.


© Publicnow 2022
All news about NEUROSENSE THERAPEUTICS LTD.
09/28NeuroSense Reports Positive Results From Study of Treatment for Amyotrophic Lateral Scl..
MT
09/28NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase ..
PR
09/28NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase ..
CI
09/21NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
PR
09/20NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PA..
PR
09/20Neurosense Therapeutics Ltd. Announces Positive Primec Toxicology Data Supportive of Cu..
CI
09/19NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotro..
PR
09/16Neurosense Therapeutics : Report Of Foreign Private Issuer - Form 6-K
PU
08/31NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update
PR
08/31NeuroSense Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, ..
CI
More news
Analyst Recommendations on NEUROSENSE THERAPEUTICS LTD.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -13,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,52x
Yield 2022 -
Capitalization 19,7 M 19,7 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 11
Free-Float 58,7%
Chart NEUROSENSE THERAPEUTICS LTD.
Duration : Period :
NeuroSense Therapeutics Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROSENSE THERAPEUTICS LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,69 $
Average target price 7,00 $
Spread / Average Target 314%
EPS Revisions
Managers and Directors
Alon Ben-Noon Chief Executive Officer & Director
Or Eisenberg Chief Financial Officer
Mark Wayne Leuchtenberger Chairman
Oron Yacoby-Zeevi Chief Scientific Officer
Ferenc Tracik Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NEUROSENSE THERAPEUTICS LTD.-30.49%20
REGENERON PHARMACEUTICALS, INC.15.89%78 242
VERTEX PHARMACEUTICALS35.99%76 586
BIONTECH SE-46.65%33 422
WUXI APPTEC CO., LTD.-39.54%29 123
GENMAB A/S5.32%23 876